Leap Therapeutics (NASDAQ: LPTX) and Mast Therapeutics (NASDAQ:SVRA) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, risk, valuation, dividends and analyst recommendations.

Valuation & Earnings

This table compares Leap Therapeutics and Mast Therapeutics’ top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
Leap Therapeutics N/A N/A -$28.35 million N/A N/A
Mast Therapeutics $400,000.00 513.71 -$16.56 million ($6.71) -1.27

Mast Therapeutics has higher revenue and earnings than Leap Therapeutics.

Profitability

This table compares Leap Therapeutics and Mast Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Leap Therapeutics N/A N/A N/A
Mast Therapeutics N/A -121.52% -65.80%

Analyst Ratings

This is a breakdown of recent ratings and price targets for Leap Therapeutics and Mast Therapeutics, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Leap Therapeutics 0 1 2 0 2.67
Mast Therapeutics 0 0 4 0 3.00

Leap Therapeutics currently has a consensus target price of $15.50, indicating a potential upside of 172.41%. Mast Therapeutics has a consensus target price of $24.50, indicating a potential upside of 188.57%. Given Mast Therapeutics’ stronger consensus rating and higher probable upside, analysts clearly believe Mast Therapeutics is more favorable than Leap Therapeutics.

Insider and Institutional Ownership

0.8% of Leap Therapeutics shares are held by institutional investors. Comparatively, 16.5% of Mast Therapeutics shares are held by institutional investors. 6.9% of Mast Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Mast Therapeutics beats Leap Therapeutics on 7 of the 9 factors compared between the two stocks.

Leap Therapeutics Company Profile

Leap Therapeutics, Inc., formerly HealthCare Pharmaceuticals, Inc., is a clinical-stage biopharmaceutical company. The Company engages in acquiring and developing therapeutics in cancer biology. Its lead product candidates for use in clinical trials include TRX518 and DKN-01. DKN-01 is a monoclonal antibody targeting Dickkopf-related protein 1 (DKK1). TRX518 is a monoclonal antibody targeting the glucocorticoid-induced tumor necrosis factor-related receptor (GITR). DKN-01 has potential as a targeted cancer treatment in esophageal cancer, cholangiocarcinoma, non-small cell lung cancer, and other tumor types, such as pancreatic, gastric, liver, head and neck, uterine, and prostate cancers and multiple myeloma. It is conducting two clinical trials of TRX518 in patients with advanced solid tumors and have evidence of biomarker modulation and clinical activity. DKN-01 has been tested in a pilot study in patients with multiple myeloma in combination with lenalidomide and dexamethasone. .

Mast Therapeutics Company Profile

Savara Inc., formerly Mast Therapeutics, Inc., is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients. Molgradex is an inhaled formulation of recombinant human granulocyte-macrophage colony-stimulating factor. It is developing Molgradex for the treatment of autoimmune pulmonary alveolar proteinosis, a rare lung disease. AIR001 is a sodium nitrite solution for inhalation via nebulization. AIR001 is in Phase II clinical development for the treatment of heart failure with preserved ejection fraction, also known as diastolic heart failure or heart failure with preserved systolic function.

Receive News & Ratings for Leap Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Leap Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.